Table 1.

Overview of patients finally included to our evaluation

Patient no.	Age	AJCC	Therapeutic agent	PERCIST / iRECIST		Overall response	NLR	RLC	REC	Spleen SUV t1-t0 (%)
				t1	t2
1*	59	IV	CTLA-4	SMD/iSD	PMD/iPD	NR	4.7	15.6	0.9	+6.8
2	74	IV	PD1	PMD/iSD	PMD/iSD	R	3.0	21.0	2.2	+32.8
3*	53	IV	PD1	PMD/iSD	PMD/iPD	NR	4.4	15.7	1.6	+16.9
4†	51	IV	CTLA-4	SMD/iSD	CMR/iCR	R	2.9	22.5	0.8	N/A
5	49	IV	PD1	PMR/iPR	CMR/iCR	R	1.5	34.6	3.1	+9.5
6*	59	IV	CTLA-4	PMD/iPD	PMD/iPD	NR	6.2	12.3	2.2	+4.2
7	84	IV	PD1	PMR/iPR	CMR/iPR	R	2.3	26.5	3.8	N/A
8	64	IV	PD1	SMD/iSD	PMD/iPD	NR	3.6	18.9	2.1	−20.5
9	75	IV	PD1	SMD/iSD	PMD/iPD	NR	4.2	17.2	0.8	−14.3
10	66	IV	PD1	SMD/iSD	SMD/iSD	R	3.5	19.6	0.5	+60.0
11	64	IV	PD1	PMD/iPD	PMD/iPD	NR	4.4	16.2	1.9	−2.3
12	60	IV	PD1	PMR/iPR	CMR/iCR	R	4.1	16.6	2.3	+25.8
13	82	IV	PD1+CTLA-4	SMD/iSD	PMR/iSD	R	3.1	22.2	1.4	+64.8
14	53	IV	PD1+CTLA-4	PMR/iSD	CMR/iPR	R	1.5	30.8	4.8	+129.9
15	76	IV	PD1+CTLA-4	PMR/iSD	PMR/iPR	R	1.7	31.7	3.0	+20.4
16†	57	IV	PD1+CTLA-4	SMD/iSD	PMD/iPD	NR	1.8	29.3	4.7	N/A
17	74	IV	PD1	SMD/iSD	PMD/iPD	NR	4.2	17.0	0.7	+2.2

†Staging of melanoma according to the AJCC eighth edition. Treatment response evaluation at t₁ and t₂ were each related to the baseline scan t₀. Overall response by taking imaging and clinical decisions into account, categorized as (Non-)Responders, (N)R. Patients with a metastatic involvement of the bone are marked with (*), of the spleen with (†). In those patients, the bone or the spleen, respectively, was excluded from further evaluation. In patient no. 7, the attenuation map at t₁ was erroneous in the upper abdomen, so no reliable SULmean of the spleen could be measured. Spleen SUV t₁-t₀ (%): the relative change of ¹⁸F-FDG-uptake of the spleen between t₁ and t₀.

*Patients with a metastatic involvement of the bone.

†Patients with a metastatic involvement of the spleen.

AJCC, American Joint Committee on Cancer; CMR, complete metabolic response; CTLA-4, cytotoxic T-lymphocyte-associated protein-4; ¹⁸F-FDG, [¹⁸F]-labeled fluorodeoxyglucose; iCR, immune complete response; iPD, immune progressive disease; iPR, immune partial response; iSD, immune stable disease; N/A, not available; NR, non-responders; PD1, programmed-death-1; PERCIST, PET response criteria in solid tumors; PMD, progressive metabolic disease; PMR, partial metabolic response; SMD, stable metabolic disease; SULmean, standardized uptake value lean body mass; SUV, standardized uptake value.